Exploring apremilast in the treatment of lichen planus pemphigoides: a new remedy

Lichen planus pemphigoides (LPP) is an uncommon autoimmune dermatosis characterized by a combination of lichenoid lesions and bullous lesions. While its pathogenesis is often considered idiopathic, some cases have been associated with certain medications and infections. The standard treatment for LPP involves systemic corticosteroids. However, the suboptimal recurrence rate of 20% and the presence of various side effects highlight the need for alternative approaches. Recognizing the role of proinflammatory cytokines in the pathogenesis of LPP and targeting their reduction and related pathways has emerged as a promising therapeutic strategy. This case report details the experience of a 67-year-old woman with a history of LPP, showing disease progression despite undergoing multiple conventional therapies. Faced with the inadequacy of traditional treatments, we achieved successful results by using apremilast as an effective intervention.